三重益生菌通过抑制巨细胞糖解依赖的亲炎性反应减轻大肠炎
Hantao Cai1, Tianxin Li1, Wanting Feng1
1The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, China; Jiangsu Key Laboratory of Molecular Medicine, Division of Immunology, Medical School, Nanjing University, Nanjing, China.
Biochemical and biophysical research communications
|December 7, 2024
概括
三重益生菌,名为Bornlisy,通过减少结肠炎症和恢复肠道健康,有效治疗小鼠的大肠炎. 这种配方调节免疫反应,为肠道炎症提供了一个有前途的治疗策略.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 益生菌是活的微生物,以其抗炎和免疫调节特性而闻名.
- 保持平衡的肠道微生态对于肠道健康至关重要.
- 大肠炎是结肠的炎症状况,需要有效的治疗干预措施.
研究的目的:
- 在大肠炎的小鼠模型中研究一种新的三重益生菌配方Bornlisy的治疗疗效.
- 阐明Bornlisy在结肠中发挥抗炎作用的机制.
- 评估Bornlisy对肠道屏障功能和肠道微生物组合的影响.
主要方法:
- 使用Lactobacillus acidophilus,Bacillus bulgaricus和Bacillus subtilis进行三重益生菌配方 (Bornlisy) 的构建.
- 将Bornlisy给诱导性大肠炎的小鼠使用.
- 评估结肠炎症,肠道屏障功能,肠道微生物组和巨细胞糖解.
主要成果:
- 在小鼠中,Bornlisy在缓解大肠炎方面表现出显著的治疗效果.
- Bornlisy抑制了结肠炎症,增强了肠道屏障功能,并恢复了不平衡的肠道微生物组.
- 博恩利斯通过抑制巨细胞糖解调节免疫反应,减轻大肠炎的进展.
结论:
- 三重益生菌Bornlisy在小鼠大肠炎的治疗中显示出显著的治疗潜力.
- 波恩利西的有效性归因于其抗炎作用,肠道屏障增强和微生物组恢复.
- 波恩利西代表了一种有前途的方法,用于临床管理肠道炎症.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
316
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
316
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119


